Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors.
T cell therapy
adenovirus
gene therapy
herpes simplex virus
immunotherapy
oncolytic virus
reovirus
solid tumor
tumor microenvironment
vaccinia virus
Journal
Molecular therapy oncolytics
ISSN: 2372-7705
Titre abrégé: Mol Ther Oncolytics
Pays: United States
ID NLM: 101666776
Informations de publication
Date de publication:
26 Jun 2020
26 Jun 2020
Historique:
received:
12
02
2020
accepted:
13
03
2020
entrez:
24
4
2020
pubmed:
24
4
2020
medline:
24
4
2020
Statut:
epublish
Résumé
Despite some promising results, the majority of patients do not benefit from T cell therapies, as tumors prevent T cells from entering the tumor, shut down their activity, or downregulate key antigens. Due to their nature and mechanism of action, oncolytic viruses have features that can help overcome many of the barriers currently facing T cell therapies of solid tumors. This study aims to understand how four different oncolytic viruses (adenovirus, vaccinia virus, herpes simplex virus, and reovirus) perform in that task. For that purpose, an immunocompetent
Identifiants
pubmed: 32322662
doi: 10.1016/j.omto.2020.03.003
pii: S2372-7705(20)30024-3
pmc: PMC7163046
doi:
Banques de données
ClinicalTrials.gov
['NCT04217473']
Types de publication
Journal Article
Langues
eng
Pagination
47-60Informations de copyright
© 2020 The Authors.
Références
Int Immunol. 2006 Nov;18(11):1521-9
pubmed: 16954167
Front Immunol. 2018 Oct 26;9:2486
pubmed: 30416506
Hum Gene Ther. 2012 Dec;23(12):1258-68
pubmed: 22985305
Clin Cancer Res. 2012 Dec 15;18(24):6679-89
pubmed: 23091113
J Clin Oncol. 2015 Sep 1;33(25):2780-8
pubmed: 26014293
Clin Cancer Res. 2013 May 15;19(10):2734-44
pubmed: 23493351
Exp Mol Med. 2018 Dec 13;50(12):1-11
pubmed: 30546008
Cancer Immunol Res. 2015 Aug;3(8):915-25
pubmed: 25977260
Nat Rev Cancer. 2002 Dec;2(12):938-50
pubmed: 12459732
Cancer. 1956 Nov-Dec;9(6):1211-8
pubmed: 13383455
Nat Med. 1999 Aug;5(8):881-7
pubmed: 10426310
J Immunother Cancer. 2019 Jan 9;7(1):6
pubmed: 30626434
Mol Ther Oncolytics. 2016 Dec 31;4:77-86
pubmed: 28345026
Dis Markers. 2019 Feb 11;2019:3425291
pubmed: 30886654
Am Soc Clin Oncol Educ Book. 2019 Jan;39:165-174
pubmed: 31099649
Clin Cancer Res. 2008 Jan 1;14(1):259-69
pubmed: 18172278
Oncoimmunology. 2015 Aug 12;5(2):e1074377
pubmed: 27057442
Curr Oncol Rep. 2012 Oct;14(5):468-74
pubmed: 22878966
Trends Cancer. 2015 Dec;1(4):266-277
pubmed: 28741515
Expert Opin Biol Ther. 2019 May;19(5):443-455
pubmed: 30905206
Eur J Immunol. 2019 Aug;49(8):1147-1152
pubmed: 31270810
Mol Ther. 2015 Jan;23(1):202-14
pubmed: 25292189
Ann Surg Oncol. 2010 Mar;17(3):718-30
pubmed: 19915919
Mol Ther. 2001 Apr;3(4):431-7
pubmed: 11319903
Mol Ther. 2015 Oct;23(10):1630-40
pubmed: 26112079
Front Pharmacol. 2017 May 16;8:270
pubmed: 28559846
BioDrugs. 2019 Oct;33(5):485-501
pubmed: 31321623
Proc Natl Acad Sci U S A. 2018 Apr 24;115(17):E4041-E4050
pubmed: 29632196
J Gen Virol. 2013 Nov;94(Pt 11):2367-2392
pubmed: 23999164
JCI Insight. 2018 Apr 5;3(7):
pubmed: 29618658
Adv Exp Med Biol. 2017;1036:51-64
pubmed: 29275464
Front Oncol. 2019 Nov 21;9:1237
pubmed: 31824840
Front Immunol. 2014 Oct 27;5:532
pubmed: 25386178
Semin Immunopathol. 2019 Jan;41(1):49-58
pubmed: 30187086
Int J Cancer. 2015 Mar 1;136(5):1065-72
pubmed: 25042001
J Gen Virol. 2015 Aug;96(8):2304-2313
pubmed: 25854552
Nat Med. 2018 Jan;24(1):20-28
pubmed: 29155426
Sci Transl Med. 2014 Mar 5;6(226):226ra32
pubmed: 24598590
Mol Ther Oncolytics. 2018 Nov 06;11:109-121
pubmed: 30569015
Protein Cell. 2018 Mar;9(3):254-266
pubmed: 28108950
Front Immunol. 2018 Sep 21;9:2103
pubmed: 30298067
J Virol. 2008 Jan;82(1):546-54
pubmed: 17942545
Blood. 2006 Sep 1;108(5):1627-34
pubmed: 16709924
Mol Ther. 2007 Apr;15(4):651-9
pubmed: 17299401
Cancer. 1974 Dec;34(6):1907-28
pubmed: 4611607
Cancer. 1952 Sep;5(5):1025-34
pubmed: 12988191
Mol Syst Biol. 2012 Apr 24;8:579
pubmed: 22531119
Cancer Res. 1949 Aug;9(8):473-80
pubmed: 18134519
Sci Transl Med. 2017 Sep 20;9(408):
pubmed: 28931654
Clin Cancer Res. 2009 Apr 15;15(8):2777-88
pubmed: 19351762
Trends Immunol. 2018 Mar;39(3):209-221
pubmed: 29275092
J Immunother Cancer. 2019 Jun 6;7(1):145
pubmed: 31171039
Oncoimmunology. 2018 Apr 9;7(5):e1412902
pubmed: 29721366
Front Immunol. 2019 Feb 08;10:168
pubmed: 30800125
Mol Ther. 2008 Oct;16(10):1665-73
pubmed: 18665155
Mol Ther. 2006 Jul;14(1):107-17
pubmed: 16690359
Clin Cancer Res. 2011 Jul 1;17(13):4550-7
pubmed: 21498393
Cancer Res. 2005 Dec 15;65(24):11255-8
pubmed: 16357128
PLoS One. 2015 Jun 24;10(6):e0131242
pubmed: 26107883
Curr Pharm Biotechnol. 2018;19(1):5-18
pubmed: 29667553
Methods Mol Biol. 2020;2060:73-90
pubmed: 31617173
Oncol Rep. 2009 Jun;21(6):1381-4
pubmed: 19424613
Clin Microbiol Rev. 2008 Oct;21(4):704-15
pubmed: 18854488
Br J Pharmacol. 2009 Oct;158(3):638-51
pubmed: 19764983
Clin Cancer Res. 2014 Aug 15;20(16):4262-73
pubmed: 24919573
Clin Cancer Res. 2012 Apr 1;18(7):2080-9
pubmed: 22316603
Front Immunol. 2018 Oct 23;9:2460
pubmed: 30405639
Cancer J. 2017 Jan/Feb;23(1):10-22
pubmed: 28114250
Virchows Arch. 2019 Apr;474(4):449-461
pubmed: 30470934
J Immunother Cancer. 2016 Sep 20;4:53
pubmed: 27660707
Oncoimmunology. 2016 Feb 18;5(5):e1136046
pubmed: 27467954
J Struct Biol. 2011 Aug;175(2):127-34
pubmed: 21419849